Medical Disclaimer: All content on this website is compiled from public user discussions for informational purposes only. This is NOT medical advice. Peptides and GLP-1 agonists are prescription compounds. Do not start, adjust or stop any treatment without consulting a licensed healthcare provider. We do not endorse any peptide vendor or medical treatment.
What GLP-1 Actually Is
GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut releases after eating. Its natural jobs: tell the pancreas to release insulin when blood sugar rises, slow stomach emptying so nutrients arrive gradually, and signal satiety to appetite circuits in the brain. It is the reason you feel full - and the reason fullness arrives a little after the last bite.
Natural GLP-1 is broken down within minutes by an enzyme (DPP-4). Medicines in this class are agonists engineered to resist that breakdown and keep activating the receptor for days rather than minutes.
How the Medicines Work
A GLP-1 receptor agonist is a molecule that binds the GLP-1 receptor and activates it, mimicking the hormone at therapeutic intensity. Approved examples include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) and - extending the mechanism - tirzepatide (Mounjaro, Zepbound), which also activates the GIP receptor.
The therapeutic effects follow directly from the receptor biology: improved glucose-dependent insulin secretion (useful in type 2 diabetes), slower gastric emptying and reduced appetite (useful in obesity treatment). The class’s side effects follow from the same biology: nausea, vomiting, diarrhea and constipation, worst during dose escalation, because the body is being asked to tolerate a stronger satiety and gastric-emptying signal than it evolved for.
Approved Medicines vs. Grey-Market Compounds
This is the distinction that matters for everything else on this site. Approved GLP-1 medicines are made in regulated manufacturing chains, with verified identity, purity, sterility and dose, prescribed under titration schedules refined in trials, and dispensed through licensed pharmacies. That entire stack is what makes the class’s trial results reproducible in practice.
Grey-market “research” versions remove every layer of that stack. Content is unverifiable without laboratory testing, dose claims are unconfirmed, sterility is unassured, and medical supervision is absent. Community-sourced third-party testing has repeatedly documented underdosing and substitution across this market. However good the underlying class is, an unverified vial is not the medicine - it is a claim wearing the medicine’s name.
Where to Read More
For the investigational triple agonist, see What Is Retatrutide?. For how buyers can verify what a vendor’s vial actually contains, see reading a COA and third-party testing. For the vendor-specific coverage that most of this site is about, start with the Nexaph Reviews overview.
Class Reference Data: Approved Compounds Compared
The clearest way to explain this class is to lay out its approved members - and one investigational member - side by side on the parameters that define them:
| Compound | Receptor targets | Approx. half-life | Schedule | Regulatory status |
|---|---|---|---|---|
| Liraglutide | GLP-1 | ~13 hours | Daily injection | Approved for obesity (as Saxenda) |
| Semaglutide | GLP-1 | ~1 week | Weekly injection | Approved for obesity (Wegovy) and T2D |
| Tirzepatide | GIP + GLP-1 | ~5 days | Weekly injection | Approved for obesity (Zepbound) and T2D |
| Retatrutide | GIP + GLP-1 + glucagon | ~6 days | Weekly in trials | Investigational - not approved in any jurisdiction |
The table tells the class’s story in one axis: mechanism count. Liraglutide (GLP-1 only, daily) established that gut-hormone mimicry could produce meaningful weight effects; semaglutide engineered a ~1-week half-life on the same single target; tirzepatide added GIP co-agonism; retatrutide adds a third target (glucagon receptor) and remains investigational. Each step added efficacy in trials and added unknowns to characterize - which is why the newest mechanism sits at the bottom of the regulatory column with “not approved” in bold.
Published efficacy across the class’s landmark trials, all from the primary journal publications:
| Compound | Trial (publication) | Duration | Dose | Mean weight change |
|---|---|---|---|---|
| Semaglutide | STEP 1, NEJM 2021 (n=1,961) | 68 weeks | 2.4 mg weekly | −14.9% vs −2.4% placebo |
| Tirzepatide | SURMOUNT-1, NEJM 2022 (n=2,539) | 72 weeks | 5 / 10 / 15 mg weekly | −15.0% / −19.5% / −20.9% vs −3.1% placebo |
| Retatrutide | Phase 2, NEJM 2023 (n=338) | 48 weeks | up to 12 mg weekly | −24.2% at the highest dose (Phase 2; investigational) |
Indication, Dosing and Usage Parameters
Beyond mechanism, the class is defined by its dosing discipline - and the dosing tables encode the tolerability lessons of every trial before them:
| Compound | Starting dose | Maintenance range | Escalation |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | 0.25 mg weekly | 2.4 mg weekly | Steps roughly every 4 weeks |
| Tirzepatide (Zepbound) | 2.5 mg weekly | 5–15 mg weekly | +2.5 mg no faster than every 4 weeks |
| Retatrutide (Phase 2 protocol) | Low protocol start | up to 12 mg weekly (trial) | Slow stepwise escalation |
The uniformity of the escalation column is the tell: every development program independently concluded that slow titration is what keeps the class’s dose-dependent gastrointestinal effects tolerable. That conclusion is written directly into the approved labels - and it is why any dosing scheme that skips titration steps is off-protocol relative to every data source the class has. The usage context is equally documented: a KFF Health Tracking Poll (May 2024) found roughly 12% of U.S. adults had ever used a GLP-1 and about 6% were current users, while Goldman Sachs Research projected the anti-obesity medication market could reach roughly $100 billion annually by 2030 - the demand backdrop that explains both licensed expansion and the grey-market overflow our vendor coverage tracks.
Where to go deeper: What Is Retatrutide? covers the investigational member; side effects tabulates the published adverse-event data; and our GLP-1 vendor-coverage page connects the class data to the market discussion around it.
Frequently Asked Questions
What does GLP-1 stand for?
Glucagon-like peptide-1, an incretin hormone released by the gut after eating. It stimulates insulin release, slows gastric emptying and reduces appetite.
Are GLP-1 agonists safe?
Approved GLP-1 medicines have well-characterized safety profiles established in large trials, with gastrointestinal side effects most common and specific warnings your prescriber will know. Safety data belongs to the regulated products, not to grey-market imitations.
Why do grey-market GLP-1s carry different risk?
Because identity, purity, dose and sterility are unverified without testing, and no medical supervision exists. The class's benefits and safety data were established for regulated products under supervision - neither transfers to an unverified vial.
What do GLP-1, GIP and glucagon receptors each do?
GLP-1 receptor agonism slows gastric emptying and reduces appetite; GIP adds a second incretin pathway with effects on insulin secretion and fat metabolism; glucagon receptor agonism adds effects on energy expenditure and appetite. Approved drugs use one or two of these targets; retatrutide uses all three and is investigational.
Are all GLP-1s weekly injections?
The current injectable mainstream is weekly (semaglutide, tirzepatide; retatrutide weekly in trials). Liraglutide, the older daily injectable, remains approved. Oral formulations exist for one approved diabetes indication of semaglutide at lower doses.
How large is usage of this class?
Per KFF (May 2024), about 12% of U.S. adults reported ever using a GLP-1 and about 6% were current users; Goldman Sachs Research projects a roughly $100-billion annual anti-obesity medication market by 2030.
Important Safety Disclaimer
Disclaimer: All content on this website is compiled from public user discussions for informational purposes only. This is NOT medical advice. Peptides and GLP-1 agonists are prescription compounds. Do not start, adjust or stop any treatment without consulting a licensed healthcare provider. We do not endorse any peptide vendor or medical treatment.